These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33993168)

  • 21. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
    Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
    Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opioids and Acute Kidney Injury.
    Mallappallil M; Bajracharya S; Salifu M; Yap E
    Semin Nephrol; 2021 Jan; 41(1):11-18. PubMed ID: 33896468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concerns among people who use opioids during the COVID-19 pandemic: a natural language processing analysis of social media posts.
    Sarker A; Nataraj N; Siu W; Li S; Jones CM; Sumner SA
    Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):16. PubMed ID: 35248103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
    Pena E; Ahmed S
    Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
    [No Abstract]   [Full Text] [Related]  

  • 25. Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic.
    Dadiomov D; Trotzky-Sirr R; Shooshtari A; Qato DM
    Drug Alcohol Depend; 2022 Mar; 232():109291. PubMed ID: 35033953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opioid maintenance, weaning and detoxification techniques; where we have been, where we are now and what the future holds: an update.
    Plunkett AR; Peden RM
    Pain Manag; 2019 May; 9(3):297-306. PubMed ID: 31140912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opioids: The Forgotten Epidemic?
    Price S
    Tex Med; 2020 Oct; 116(10):32-35. PubMed ID: 33126270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia.
    Roberts J; White B; Attalla D; Ward S; Dunlop AJ
    Addiction; 2021 Feb; 116(2):426-427. PubMed ID: 32888226
    [No Abstract]   [Full Text] [Related]  

  • 29. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.
    Krawczyk N; Fawole A; Yang J; Tofighi B
    Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH; Cales SC; Shreffler J; Huecker MR
    J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opioid Use Disorder and COVID-19: Crashing of the Crises.
    Khatri UG; Perrone J
    J Addict Med; 2020; 14(4):e6-e7. PubMed ID: 32404651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measuring the Burden of Opioid-Related Mortality in Ontario, Canada, During the COVID-19 Pandemic.
    Gomes T; Kitchen SA; Murray R
    JAMA Netw Open; 2021 May; 4(5):e2112865. PubMed ID: 34037734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.
    Bach P; Hartung D
    Addict Sci Clin Pract; 2019 Sep; 14(1):30. PubMed ID: 31474225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
    Gustafson DH; Landucci G; McTavish F; Kornfield R; Johnson RA; Mares ML; Westergaard RP; Quanbeck A; Alagoz E; Pe-Romashko K; Thomas C; Shah D
    Trials; 2016 Dec; 17(1):592. PubMed ID: 27955689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revising our attitudes towards agonist medications and their diversion in a time of pandemic.
    Del Pozo B; Rich JD
    J Subst Abuse Treat; 2020 Dec; 119():108139. PubMed ID: 33138924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder.
    Wilson CG; Ramage M; Fagan EB
    J Rural Health; 2021 Jan; 37(1):169-171. PubMed ID: 32277732
    [No Abstract]   [Full Text] [Related]  

  • 37. Pregnant Patients Using Opioids: Treatment Access Barriers in the Age of COVID-19.
    Lensch AC; Hairston E; Carter G; Jones HE
    J Addict Med; 2022 Jan-Feb 01; 16(1):e44-e47. PubMed ID: 33606424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here?
    Tracy K; Wachtel L; Friedman T
    J Subst Abuse Treat; 2021 Dec; 131():108394. PubMed ID: 34098292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Access to Healthcare and Harm Reduction Services During the COVID-19 Pandemic for People Who Use Drugs.
    Stowe MJ; Calvey T; Scheibein F; Arya S; Saad NA; Shirasaka T; Dannatt L; Ghosh A; Yee A; Ratta-Apha W; Vadivel R; Siste K; Shah B; Ramalho R; Narasimha VL; Delic M; Peyron E; Onoria JLG; Pant SB; Boujraf S; Grandinetti P; Morgan N
    J Addict Med; 2020 Dec; 14(6):e287-e289. PubMed ID: 33009167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: Should this practice be incorporated into routine clinical care?
    Trujols J; Larrabeiti A; Sànchez O; Madrid M; De Andrés S; Duran-Sindreu S
    J Subst Abuse Treat; 2020 Dec; 119():108154. PubMed ID: 33032860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.